Podcasts about approvals

Aytekin is the founder and CEO of JotForm, one of the most widely used no-code automation platforms in the world, serving more than 35 million users across education, healthcare, nonprofits, and small businesses. He's also the author of the Wall Street Journal and Publisher's Weekly bestselling book Automate Your Busy Work,00:00 – IntroductionFounder mindset, automation philosophy, and the future of work00:01 – Why Automate Your Busy Work Was Ahead of Its TimeNo-code, automation thinking before the AI boom01:09 – Building JotForm Before the AI Hype Cycle20 years of bootstrapping, slow growth, and real product-market fit02:29 – Forms as the Gateway to AutomationHow education, nonprofits, healthcare, and SMBs really work03:49 – From Forms to Workflows, Approvals, PDFs, and E-SignaturesDesigning automation for people without developers04:21 – Solo Founder Reality: Doing HR, Legal, Support, and Product AloneThe hidden cognitive cost of running everything yourself04:51 – Competing with Google Forms as a Bootstrapped FounderWhy automation and delegation became survival tools05:58 – Email Automation as Cognitive ReliefHow prioritization systems reduce stress and decision fatigue07:41 – Applying Automation Internally: Teams, CI/CD, and TestingWhy automation makes teams safer, not riskier08:10 – Designing Products Around How People Actually WorkFrom tools to systems thinking09:17 – Writing, Teaching, and Sharing Automation PrinciplesFrom Medium and Forbes to a bestselling book10:48 – Discovering the AI Revolution After Publishing the BookAutomation philosophy vs AI productivity tools11:16 – “People Aren't Overworked — They're Over-Busy”The psychology of modern work and burnout12:28 – Embodying Automation Principles Inside the CompanyScaling without chaos12:48 – Email Prioritization Systems That Actually WorkHow to design inboxes for executives and founders14:20 – Gmail Filters, Labels, and Decision AutomationSimple systems over complex tools16:59 – Automation as Stress Reduction, Not SpeedWhy missing important work causes burnout19:21 – Continuous Deployment and First-Day Code CommitsHow automation builds trust and confidence at scale21:12 – Why Automation Shouldn't Be FearedRisk reduction through systems22:08 – Internal Automation Lessons from JotForm's Engineering Culture23:01 – Future of Work: Policy, Strategy, and AIWEF, global work, and structural change24:32 – Does AI Kill Jobs or Create Better Ones?A real company case study25:02 – Deploying AI Support Without Laying Off EmployeesHow JotForm handled AI responsibly27:09 – Human-in-the-Loop AI SystemsWhy oversight matters more than hype28:19 – Training AI Through Documentation and FeedbackHow resolution rates improved from 25% to 75%31:01 – Improving AI Through Better Knowledge SystemsDocumentation as infrastructure32:36 – New Roles Created by AI AdoptionFrom support agents to AI evaluators33:29 – Multilingual AI Support at Global ScaleWhy AI enables inclusion, not just efficiency35:09 – Why JotForm Didn't Get AcquiredIndependence, focus, and long-term thinking39:29 – Focused Work, Fewer Hours, Higher LeverageRedefining productivity at scale41:06 – Evolution of JotForm Into a Full Automation PlatformFrom forms to AI agents and integrations42:09 – AI Agents Demo Discussion and Key TakeawaysReal use cases, real ROI46:18 – User Research at Massive ScaleLearning from 35 million users48:03 – Omnichannel AI Agents: Web, Instagram, Gmail, SalesforceTraining once, deploying everywhere49:35 – The Future of AI Agents as Digital EmployeesOne system, many touchpoints50:14 – Advice for Young Developers and FoundersHow to compete in the AI era50:49 – Growth Mindset Through Every Tech RevolutionFrom PCs to the internet to AI52:10 – Why This Is the Best Time to Be YoungOpportunities created by AI and no-code tools53:38 – Closing Reflections on Building, Learning, and PurposeA long-term view of work and life

The New York State Gaming Commission has officially approved three full-scale commercial casino licenses for sites in Queens and the Bronx. Plus, how much are New Yorkers paying for Christmas trees these days?

Part 3 of Jen Suzuki's 4-part manager mini-series goes deep into one of the most profitable coaching skills in the dealership: teaching teams how to gain more service approvals using her formula called Job–Risk–Reward (JRR). Jen breaks down exactly how to train advisors, salespeople, and BDC agents to explain value simply, clearly, and with confidence — without scripts. You'll learn how to teach the formula in minutes, demonstrate it live, then drive real application with team exercises, role-play, and even spicy contests that make learning stick. From wipers and brake pads to leather seats and display screens, Jen shows you how this formula boosts trust, increases transparency, and gets customers saying yes more often. This is your playbook for fast, high-impact coaching that drives approvals, customer loyalty, and profitability. Dealer Talk with Jen Suzuki Podcast |

Marriage green cards in 2026: 2-3 month approvals for adjustment of status (incredibly fast!) but with major new risks under the Trump administration.

BUSINESS: Investment approvals still well below target | Dec. 9, 2025Subscribe to The Manila Times Channel - https://tmt.ph/YTSubscribe Visit our website at https://www.manilatimes.net Follow us: Facebook - https://tmt.ph/facebook Instagram - https://tmt.ph/instagram Twitter - https://tmt.ph/twitter DailyMotion - https://tmt.ph/dailymotion Subscribe to our Digital Edition - https://tmt.ph/digital Check out our Podcasts: Spotify - https://tmt.ph/spotify Apple Podcasts - https://tmt.ph/applepodcasts Amazon Music - https://tmt.ph/amazonmusic Deezer: https://tmt.ph/deezer Stitcher: https://tmt.ph/stitcherTune In: https://tmt.ph/tunein#TheManilaTimes#KeepUpWithTheTimes Hosted on Acast. See acast.com/privacy for more information.

This week in The Weekly Investor News, the big story isn't about another grant or another scheme — it's about the one thing that truly drives long-term property values:

“I will be doing a ONE RULE Executive Order this week,” Trump posted on social media. “You can't expect a company to get 50 Approvals every time they want to do something.” Paramount Skydance on Monday launched a hostile, $108.4 billion bid to buy Warner Bros. Discovery, days after Warner Bros. agreed to be acquired by Netflix for $82.7 billion. Learn more about your ad choices. Visit podcastchoices.com/adchoices

In March 2022, Dr. Joseph Fraiman taped an internal call between FDA directors and physicians who were concerned about mRNA side effects in their patients – including the cardiac arrest and sudden death of a 7-year-old days after being injected with Pfizer's mRNA vaccine. “This was a top level meeting of directors,” Dr. Fraiman revealed to Ask Dr. Drew in Sept 2023. “This entire meeting terrified my entire work group.” The call – legally recorded by Dr. Fraiman – included FDA Director Dr. Peter Marks, Dr. Peter Doshi, Dr. Celia Witten, Dr. Sarah Walinsky, Dr. Lorrie McNeill, and many other experts. “What they're saying here is they're not doing statistical testing on adverse events. This is really insane to me,” Dr. Fraiman continued. “You know there's a problem if the vaccine group has a higher rate of them.” Dr. Joseph Fraiman, MD is an emergency physician and clinical researcher focused on harm-benefit analysis. He served as Medical Manager of Louisiana's Urban Search Rescue Disaster Task Force 1 and is lead author of a widely known re-analysis of mRNA vaccine serious harms. Follow at https://x.com/josephfraiman Dr. Stephanie Venn-Watson is Co-CEO and Co-Founder of Seraphina Therapeutics. She is a veterinary epidemiologist and author of “The Longevity Nutrient” (March 2025). Her background includes DARPA, the U.S. Navy Marine Mammal Program, and research on nutritional C15:0 deficiencies. Learn more at https://drdrew.com/fatty15 「 SUPPORT OUR SPONSORS 」 • AUGUSTA PRECIOUS METALS – Thousands of Americans are moving portions of their retirement into physical gold & silver. Learn more in this 3-minute report from our friends at Augusta Precious Metals: ⁠⁠⁠⁠https://drdrew.com/gold⁠⁠⁠⁠ or text DREW to 35052 ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠• FATTY15 – The future of essential fatty acids is here! Strengthen your cells against age-related breakdown with Fatty15. Get 15% off a 90-day Starter Kit Subscription at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/fatty15⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • PALEOVALLEY - "Paleovalley has a wide variety of extraordinary products that are both healthful and delicious,” says Dr. Drew. "I am a huge fan of this brand and know you'll love it too!” Get 15% off your first order at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/paleovalley⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • VSHREDMD – Formulated by Dr. Drew: The Science of Cellular Health + World-Class Training Programs, Premium Content, and 1-1 Training with Certified V Shred Coaches! More at https://drdrew.com/vshredmd • THE WELLNESS COMPANY - Counteract harmful spike proteins with TWC's Signature Series Spike Support Formula containing nattokinase and selenium. Learn more about TWC's supplements at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twc.health/drew⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ 「 ABOUT THE SHOW 」 Ask Dr. Drew is produced by Kaleb Nation (⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://kalebnation.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠) and Susan Pinsky (⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twitter.com/firstladyoflov⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠e⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠). This show is for entertainment and/or informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment. Executive Producers • Kaleb Nation - ⁠⁠⁠⁠⁠⁠⁠⁠https://kalebnation.com⁠⁠⁠⁠⁠⁠⁠⁠ • Susan Pinsky - ⁠⁠⁠⁠⁠⁠⁠⁠https://x.com/firstladyoflove⁠⁠⁠⁠⁠⁠⁠⁠ Content Producer & Booking • Emily Barsh - ⁠⁠⁠⁠⁠⁠⁠⁠https://x.com/emilytvproducer⁠⁠⁠⁠⁠⁠⁠⁠ Hosted By • Dr. Drew Pinsky - ⁠⁠⁠⁠⁠⁠⁠⁠https://x.com/drdrew⁠⁠⁠⁠⁠⁠⁠⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

This month we continue the theme of planning, not business planning but farm development planning and approvals. My guest, Wendy Goodburn, a NSW DPIRD Land Use Planner joins us to explain the development and recent release of a fantastic, freely available online tool called myFarmPlanner. myFarmPlanner assists farmers, planners, consultants and local government with the pre-lodgement process for development applications related to on farm developments and upgrades. It is designed for the dairy, horticulture, poultry and agritourism industries in NSW.While this is an audio only podcast and while we can't actually show you what the tool looks like, you can view our recently recorded Dairy Breakfast webinar which was very well received and shows the tool being used live with a NSW dairy farm. A link to the recording is in the show notes and can also be found on the NSW Agriculture YouTube page in the Dairy playlist.Useful resources related to this podcast:·       Dairy Business Breakfast webinar showcasing myFarmPlanner·       myFarmPlanner·       Industry resources for planning and development including “NSW Dairy Development and Environmental Guidelines 2024”, “Farm System Evaluator” tool and the “National Guidelines – Dairy Feedpads and Contained Housing”·       NSW Agricultural Land Use Planning website  This podcast is an initiative of the NSW DPI Dairy Business Advisory Unit – further information and resources are available here - Dairy | Department of Primary IndustriesIt is brought to you in partnership the Hunter Local Land ServicesPlease share this podcast with your fellow farmers and colleagues and feel free to contact us with suggestions or comments via this email address thebusinessofdairy@gmail.comFurther NSW DPI Dairy channels to follow and subscribe to include:NSW DPI Dairy Facebook pageNSW DPI Dairy Newsletter - Connect with us | Department of Primary Industries Transcript hereProduced by Liam DriverThe information discussed in this podcast are for informative and educational purposes only and do not constitute advice. 

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve deep into a series of transformative events that underscore the dynamic nature of our industry, where scientific innovation meets regulatory evolution and market adaptation.We begin with significant regulatory news from Medicare, which recently announced price reductions for 15 prescription drugs, including Novo Nordisk's semaglutide products, Ozempic and Wegovy. This initiative is part of the Inflation Reduction Act aimed at making essential medications more affordable. By potentially increasing accessibility to these treatments, this move highlights a growing trend towards cost containment in drug pricing within the U.S. healthcare system. It reflects a broader effort to ensure that life-saving treatments remain within reach for more patients, emphasizing the need for balance between innovation and affordability.Turning to approvals, Otsuka has secured FDA clearance for Voyxact, a first-in-class treatment targeting IgA nephropathy (IgAN). This positions Otsuka in an increasingly competitive market space populated by major players like Novartis and Vertex. The entry of Voyxact could pave the way for innovative therapeutics in kidney diseases, offering new hope to patients who have had limited treatment options until now.On the other side of the Atlantic, French authorities have conducted a raid on Sanofi's headquarters as part of a tax fraud investigation. This development sheds light on ongoing scrutiny in the pharmaceutical sector regarding financial practices and regulatory compliance. Such investigations can have far-reaching implications on corporate governance and transparency, reminding us of the importance of ethical practices in maintaining industry trust.Novo Nordisk has strategically used its FDA national priority voucher to expedite the review process for a high-dose formulation of Wegovy. This move underscores the importance of regulatory incentives in accelerating drug development timelines, allowing for quicker patient access to potentially life-changing therapies. It's a testament to how strategic navigation through regulatory pathways can significantly impact drug availability.In clinical trials, Sarepta Therapeutics received FDA clearance to conduct a study combining its gene therapy Elevidys with sirolimus in patients with Duchenne muscular dystrophy. The study aims to address liver safety issues associated with Elevidys, which had led to previous label restrictions. This reflects the industry's commitment to enhancing therapeutic safety profiles while expanding treatment indications.In oncology advancements, AstraZeneca's Imfinzi received FDA approval for use in early-stage stomach cancer, marking its third perioperative indication. This approval underscores the expanding role of immunotherapy across various cancer types and stages, offering new treatment paradigms that could improve surgical outcomes and long-term patient survival.Despite these advances, there is skepticism regarding artificial intelligence's role in regulatory compliance submissions among pharmaceutical professionals. A survey reveals that 65% express distrust towards AI-generated outputs, highlighting challenges that AI technologies face in gaining acceptance within highly regulated environments such as pharmaceuticals. However, federal recommendations to revamp U.S. biotechnology research emphasize incorporating AI into scientific processes to maintain global competitiveness. This call reflects concerns over potential declines in innovation leadership and underscores the need for strategic investment in research infrastructure.In antitrust news, the Federal Trade Commission (FTC) outlined its case agaiSupport the show

In this episode of the Vital Health Podcast, host Duane Schulthess speaks with Dr. Malina Müller, Head of Health Economics at WifOR Institute, to explore the heated debate around accelerated and conditional approvals in Europe, how demographic and budget pressures shape HTA decisions, the tradeoffs between surrogate endpoints and overall survival, the challenges of using real world evidence under GDPR, and the broader pricing and competitiveness threats facing Europe’s life science ecosystem. Key Topics: Accelerated Approvals: Uncertainty versus early access, conditional pathways in Europe, and costs of delayed treatment. Health System Pressures: Aging populations, fixed-price hospital incentives, cross-country budget constraints. Endpoints & Evidence: Surrogate versus overall survival, patient-reported outcomes, practical limits of real-world evidence in Europe. HTA & Harmonization: Germany's strict assessments, JCA and EMA alignment, and equity gaps across member states. Global Pricing Risks: Most Favored Nation (MFN) proposals, launch delays between the FDA and EMA, and Europe’s competitiveness versus China. Opinions expressed are those of the speakers.See omnystudio.com/listener for privacy information.

The FDA's Accelerated Approval Program (AAP) aims to bring promising, potentially life-saving medicines to patients sooner by allowing approvals based on surrogate endpoints while requiring timely confirmatory evidence. In this episode, we speak with Bridget Doherty, MPH, MS (Johnson & Johnson Innovative Medicine), and Jeff Allen, PhD (Friends of Cancer Research). Bridget discusses her team's review of the AAP's real-world impact, showing that hundreds of thousands of meaningful life-years have been gained for patients. Jeff shares findings from work strengthening biomarkers as reliable surrogate endpoints—helping define when increased speed can still preserve scientific rigor. We also explore the core access challenge: how payer coverage and utilization management help or hinder patients the AAP is designed to serve. We close with practical policy steps to ensure that earlier regulatory access truly leads to better outcomes for people who need treatments most. Bridget Doherty, MPH, MS, Johnson & Johnson Jeff Allen, Friends of Cancer Research J&J Center for U.S. Healthcare Policy Research Friends of Cancer Research Accelerated Approvals in Oncology Tracker Drug Development Dashboards 30 Years of Accelerated Approval: Data-Driven Insights Analysis of FDA Biomarker Qualification Program Original JNCCN Study How Gleevec Transformed Leukemia Treatment Immunotherapy Surrogate Endpoints Confirmatory Trials Years Gained from the FDA Accelerated Approval Program (2024) Circulating Tumor DNA (ctDNA) ctMoniTR Project Questions or comments? Email us at comments@prescriptionforbetteraccess.com. Find us on social media: X, LinkedIn, YouTube, and Threads.

Red tape continues to tie up New Zealand's agriculture and horticultural sectors. Animal and Plant Health NZ's annual survey finds nearly half its members feel regulatory performance has worsened, despite recommendations put forward by the Ministry for Regulation earlier this year. Chief executive Liz Shackleton told Mike Hosking despite reassurance from regulators, the day-to-day process is not getting easier. She says farmers and growers face a raft of challenges and don't have the right tools for the job. She says it's a real handbrake on economic growth, and we're missing out on better environmental outcomes. LISTEN ABOVE See omnystudio.com/listener for privacy information.

Pharmacists play a critical role in infectious disease care, and staying up to date on antibiotic therapies is key to ensuring optimal patient outcomes. This episode reviews recently FDA-approved antibiotics, offers a practical refresher on commonly used antibiotic classes, and highlights frequent side effects—along with strategies for managing them in practice. Tune in to strengthen your clinical knowledge and support safe, effective antibiotic use across care settings.HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTHunter Rondeau, PharmD, BCIDP, AAHIVPAntimicrobial Stewardship CoordinatorSSM HealthJoshua Davis Kinsey has no relevant financial relationships with ineligible companies to disclose. Hunter Rondeau is a consultant for Pyrls, a speaker for ASHP, and was a speaker for ACCP (ended October 2025) and Vituity (ended May 2025). All relevant financial relationships have been mitigated.  Pharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/CPE INFORMATION Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Identify newly FDA-approved antibiotics and their clinical indications.2. Describe commonly used antibiotic classes, their typical side effects, and strategies to manage or mitigate those effects.0.05 CEU/0.5 HrUAN: 0107-0000-25-362-H01-PInitial release date: 11/24/2025Expiration date: 11/24/2026Additional CPE details can be found here.

Pharmacists play a critical role in infectious disease care, and staying up to date on antibiotic therapies is key to ensuring optimal patient outcomes. This episode reviews recently FDA-approved antibiotics, offers a practical refresher on commonly used antibiotic classes, and highlights frequent side effects—along with strategies for managing them in practice. Tune in to strengthen your clinical knowledge and support safe, effective antibiotic use across care settings. HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTHunter Rondeau, PharmD, BCIDP, AAHIVPAntimicrobial Stewardship CoordinatorSSM HealthJoshua Davis Kinsey has no relevant financial relationships with ineligible companies to disclose. Hunter Rondeau is a consultant for Pyrls, a speaker for ASHP, and was a speaker for ACCP (ended October 2025) and Vituity (ended May 2025). All relevant financial relationships have been mitigated.   CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:If you are already enrolled in this course, click here to redeem your credit. To purchase this episode and claim your CPE credit, click here. CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Identify newly FDA-approved antibiotics and their clinical indications.2. Describe commonly used antibiotic classes, their typical side effects, and strategies to manage or mitigate those effects.0.05 CEU/0.5 HrUAN: 0107-0000-25-362-H01-PInitial release date: 11/24/2025Expiration date: 11/24/2026Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

In this episode of Talk Property To Me, hosts Brad East and Aaron Downie unpack one of Australia's biggest issues right now: building approvals are rising, but construction output is falling — all while the country faces the largest population boom on record. Australia approved more homes than ever in 2024–2025, yet fewer houses are actually being built. In this episode, we break down the real reasons behind the housing supply crunch — from labour shortages, skyrocketing material costs and developer feasibility, to the impact of surging investor lending and record migration.  We also analyse how government planning reforms, council delays, CDC pathways and the Housing Future Fund are affecting supply, rental prices, and long-term affordability for first-home buyers and investors.

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a landscape marked by significant scientific advancements, regulatory approvals, and strategic shifts that are reshaping the industry.Starting with Regeneron, the company's ophthalmic drug Eylea HD has recently secured two FDA approvals. These endorsements not only grant a new indication but also introduce a more flexible dosing regimen. This positions Eylea HD competitively against Roche's Vabysmo, highlighting the importance of regulatory navigation and strategic positioning in the pharmaceutical sector. These approvals come after extensive negotiations with both the FDA and third-party manufacturers, emphasizing the intricate processes involved in bringing a drug to market.In oncology, Bayer has achieved an accelerated FDA approval for Hyrnuo, a treatment targeting HER2-mutated non-small cell lung cancer. This move allows Bayer to challenge Boehringer Ingelheim's Hernexeos, underscoring the fiercely competitive nature of the oncology market. Such advancements are driven by innovative treatments that address specific genetic mutations in cancer patients, reflecting a broader trend towards precision medicine.Meanwhile, Moderna is investing heavily in mRNA production capabilities with a new $140 million facility in Norwood, Massachusetts. This development underscores Moderna's commitment to mRNA technology, which gained significant attention during the COVID-19 pandemic. The facility aims to establish robust domestic manufacturing infrastructures to mitigate supply chain vulnerabilities—a critical move considering recent global disruptions.Novartis is also making headlines with its plans for a flagship production hub in North Carolina. This expansion is expected to create 700 jobs and expand its manufacturing footprint by 700,000 square feet, highlighting Novartis's strategic emphasis on scaling up operations to meet growing demands and enhance production efficiency.In another strategic collaboration, Antheia has joined forces with Teva's TAPI division to enhance the commercialization prospects for its biosynthetic pipeline. This alliance marks a significant step toward advancing biologically derived pharmaceuticals, promising to revolutionize drug production through more sustainable and scalable alternatives to traditional chemical synthesis.On the regulatory front, Merck has received broad EU approval for a subcutaneous formulation of Keytruda. This development could significantly expand Keytruda's market reach across Europe, demonstrating how regulatory agility can extend drug lifecycles and maximize therapeutic impact across diverse patient populations.Compliance challenges remain prevalent, as illustrated by Pfizer and Tris Pharma's settlement of allegations related to ADHD medication Quillivant's quality control issues for $41.5 million. This case highlights ongoing efforts to ensure stringent quality standards within pharmaceutical manufacturing processes.Abbott is expanding its diagnostics portfolio through a $23 billion acquisition of Exact Sciences, known for its Cologuard colorectal cancer test. This acquisition indicates a strategic shift towards enhancing diagnostic capabilities alongside therapeutic offerings—a trend increasingly evident in holistic healthcare solutions.GSK is embarking on a $7 billion collaboration with biotechs Quotient and Profound through Flagship Pioneering. This partnership aims to leverage novel protein and genomic technologies to drive innovation in drug discovery and development, illustrating the industry's focus on integrating advanced biotechnological insights into traditional pharmaceutical frameworks.These developments collectively underscore crSupport the show

Ontario -Express Entry: Skilled Trades Stream – Suspension and Return of Applications, released by Ontario on  November 14 2025 Good day ladies and gentlemen, this is IRC news, I am Joy Stephen, a certified Canadian Immigration practitioner, and I bring to you this Provincial News Bulletin from the province of Ontario. This recording originates from the Polinsys studios in Cambridge, Ontario. Express Entry: Skilled Trades Stream – Suspension and Return of Applications  The Ontario Immigrant Nominee Program (OINP) has conducted a review of the OINP's Express Entry: Skilled Trades Stream (Skilled Trades Stream) and has identified systemic compliance and enforcement concerns relating to the stream.  In particular, the review identified systemic misrepresentation and/or fraud relating to Skilled Trades Stream eligibility criteria. These issues affect the ability of the director appointed under the Ontario Immigration Act, 2015 (Director) to determine whether applicants meet eligibility criteria.  As currently structured, the Skilled Trades Stream is vulnerable to systemic misrepresentation and/or fraud. This vulnerability undermines the Skilled Trades Stream's ability to meet the immediate labour market needs of the province, taking into account Ontario's limited nomination allocation. As a result, the Director:  has suspended receiving Skilled Trades Stream applications will return all outstanding Skilled Trades Stream applications in accordance with section 7 of Ontario Regulation 421/17 (Approvals under the Ontario Immigrant Nominee Program and Other Matters).  Applications that are returned will have their application fees refunded.  Applicants who remain interested in the program and meet the eligibility criteria for one of the other OINP's streams may submit a new Expression of Interest (EOI) to be considered for future draws.   |  You can always access past news from the Province of Ontario by visiting this link: https://myar.me/tag/on/. Furthermore, if you are interested in gaining comprehensive insights into the Provincial Express Entry Federal pool Canadian Permanent Residence Program or other Canadian Federal or Provincial Immigration programs, or if you require guidance after your selection, we cordially invite you to connect with us through https://myar.me/c. We highly recommend participating in our complimentary Zoom resource meetings, which take place every Thursday. We kindly request you to carefully review the available resources. Should any questions arise, our team of Canadian Authorized Representatives is readily available to address your concerns during the weekly AR's Q&A session held on Fridays. You can find the details for both of these meetings at https://myar.me/zoom. Our dedicated team is committed to providing you with professional assistance throughout the immigration proSupport the show

The Friday Five for November 14, 2025: iPhone Pocket Brings Back… Pockets. CMS Rural Health Transformation Program Government Shutdown Update Most-Favored Nation Drug Pricing CMS GENEROUS Model   Get Connected:

In today's Cloud Wars Minute, I unpack how Microsoft is empowering business users with new Copilot agents that simplify app creation and workflow automation — no coding needed.Highlights00:11 — Microsoft has launched a series of new agents for Microsoft 365 Copilot customers in the Frontier Program: App Builder and Workflows, designed to accelerate the creation of AI-driven apps and workflows. These agents make it incredibly easy for general business users to utilize natural language in order to create apps, workflows, and even additional agents.00:46 — The Workflows agent allows users to automate tasks such as email, mail apps, and calendar management across Outlook, Teams, SharePoint, Planner, and other services like Approvals. Steps of the automation are displayed in real time and follow the same Copilot conversation, making it easy to add more or edit existing workflow steps.01:24 — In a blog post, Charles Lamanna, President of Business and Industry Copilot at Microsoft, outlined a use case for these new agents: "Imagine you're preparing for a product launch with a few multi-turn interactions. Create an app for a product launch process where teams can track launch milestones, assign tasks, and view campaign progress in a dashboard."01:37 — "Send a Teams update every Monday with upcoming launch deadlines and key tasks from Planner. Post reminders for approval deadlines in Teams channels. Build an agent that answers product launch questions like: “What's the next milestone?”, “How do I submit creative assets?”, or “When is the launch event?”, using SharePoint resources and Teams conversations."02:08 — Regarding Microsoft's strategy for Copilot: step one involved integrating Copilot everywhere to ensure easy access and increasing familiarity. Step two was the launch of Copilot Studio Lite, which allows any user to build agents easily. Now, step three is focusing on finding the off-the-shelf agents available to make complex tasks such as app development and workflow automation seamless. Visit Cloud Wars for more.

Subscribe to UnitedHealthcare's Community & State newsletter.In this episode, Rob Lott interviews Jennifer Kao of the UCLA Anderson School of Management in front of a live audience about her paper in the October 2025 issue of Health Affairs exploring the impact of risk evaluation and mitigation strategies on generic approvals of US pharmaceutical products.Order the October 2025 issue of Health Affairs.Currently, more than 70 percent of our content is freely available - and we'd like to keep it that way. With your support, we can continue to keep our digital publication Forefront and podcast Subscribe to UnitedHealthcare's Community & State newsletter.

TransLink's Rapid Transit Program faces major funding hurdles as plans for nine new Bus Rapid Transit lines continue to stall.   Read the full article here: https://www.coastalfront.ca/read/translink-bus-rapid-transit-expansion-at-impasse-despite-approvals   PODCAST INFO:

See omnystudio.com/listener for privacy information.

In this episode of Dealer Talk with Jen Suzuki, I break down how to take everything from the previous service advisor lessons — warm greetings, Job-Risk-Reward (JRR), analogies, and MPI preparation — and execute a 2.0 follow-up call that drives approvals. I'll cover: How to personalize each call and start with a warm, human touch Using good news first to relax customers before addressing needed work Incorporating JRR and analogies to make repairs clear and relatable Strategies for texts and follow-ups when customers don't pick up Tracking approvals and keeping momentum for a seamless customer experience Dealer Talk with Jen Suzuki Podcast |

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world. ##FDA Approves New Cancer TreatmentThe FDA has approved a new cancer treatment that has shown promising results in clinical trials. This treatment is expected to provide a new option for patients who have not responded well to traditional therapies. ##Drug Company Announces Major Breakthrough in Alzheimer's ResearchA drug company has announced a major breakthrough in Alzheimer's research, with a new drug that has shown significant improvement in cognitive function in patients with the disease. This breakthrough could potentially change the way Alzheimer's is treated in the future. ##Biotech Startup Raises $50 Million in FundingA biotech startup has raised $50 million in funding to further develop its innovative technology. This funding will allow the company to continue its research and development efforts, with the goal of bringing new treatments to market. ##Pharma Company Expands Manufacturing FacilitiesA pharmaceutical company has announced plans to expand its manufacturing facilities in order to meet growing demand for its products. This expansion will create new jobs and increase production capacity, allowing the company to better serve its customers. ##New Study Shows Promising Results for Diabetes TreatmentA new study has shown promising results for a potential new treatment for diabetes. The treatment, which targets a specific pathway in the body, has shown significant improvements in blood sugar levels and insulin sensitivity in patients with type 2 diabetes. ##Biotech Company Collaborates with Research Institute on Rare Disease TreatmentA biotech company has announced a collaboration with a research institute to develop a new treatment for a rare disease. This partnership brings together expertise from both organizations to work towards finding a cure for this debilitating condition. ##FDA Issues Warning About Counterfeit DrugsThe FDA has issued a warning about counterfeit drugs being sold online. These drugs may not contain the proper ingredients or may be contaminated, posing serious risks to consumers who purchase them. It's important to only buy medications from reputable sources to ensure safety and effectiveness.Support the show

Learning concepts is only half the battle — the real skill comes from practice. In this episode of Dealer Talk with Jen Suzuki, I share an interactive activity from my live classes that helps service advisors take everything they've learned — from warm greetings to Job-Risk-Reward explanations and analogies — and put it into action using real MPIs. I'll cover: How to use MPIs, photos, and videos to plan conversations Partnered role-play exercises to practice greetings, JRR, and analogies Tips for managers to coach their teams during practice Turning practice into confidence so live customer conversations feel effortless A weekly challenge: pick two MPIs, create analogies, practice, get feedback, and level up your team When advisors practice in a safe environment, their confidence rises, explanations become clear, and customer trust — and approvals — soar. Dealer Talk with Jen Suzuki Podcast |

PR isn't dead—it's evolved. And most brands are still playing by the old rulebook.In this episode we sit down with three communications leaders to dissect how modern PR actually works: Pippa Doyle (Global PR at Whoop), Shireen McDonagh (Brand & Content at Legacy Communications), and Niamh Hopkins (Head of Consumer PR at Legacy).This isn't theory. You'll hear the real story of how an agency changed a client's mind with a single email. Why Whoop runs exclusive events instead of chasing scale. How Krispy Kreme owned the news cycle in 24 hours when Leo Varadkar resigned. And why "freedom through structure" unlocks better creative than open-ended briefs.If you're a marketer, brand leader, or agency professional wondering why your PR feels stuck in 2010, this conversation will rewire how you think about communications, content, and building brand fame in a cluttered market.What You'll Learn:Why PR should be renamed "communications" (and what that shift actually means)The briefing framework that gets agencies to do their best workHow to turn one event into months of content across every channelThe truth about influencer numbers vs. engagement (and when each matters)Why budget constraints unlock creativity instead of killing itThe "brand newsroom" model and who should be your editor-in-chiefHow smaller brands can win with agility against bigger competitorsCHAPTERS:00:00 - Introduction: The Evolution of PR02:15 - Why "PR" Needs to Become "Communications"04:25 - Case Study: How One Email Changed a Client's Mind07:00 - What PR Actually Drives: Fame, Awareness & Word of Mouth10:04 - Why Great Campaigns Start With Great Briefs11:16 - The "Freedom Through Structure" Briefing Framework13:14 - Why Budget Can Be a Beautiful Constraint14:27 - Events as Content Machines, Not One-Day Moments18:27 - Measuring Event Success: Beyond Who Showed Up19:45 - Working With Influencers & Creators: Authenticity First23:06 - Does Follower Count Actually Matter?26:45 - Reactive Content Done Right: Aldi's Oasis & Krispy Kreme's Leo Moment28:00 - The Brand Newsroom Model: Operating Like a Publisher29:14 - Speed, Approvals & Team Alignment32:05 - Practical Advice: Setting Up Your Comms Function for Success37:52 - The Editor-in-Chief Role: Who Defends the Idea?with Legacy Communications Hosted on Acast. See acast.com/privacy for more information.

Specs, millimeters, torque, hydraulic pressure… customers check out FAST when advisors go “full tech mode.” That's where analogies change the game. In this episode of Dealer Talk with Jen Suzuki, I share one of my favorite techniques that helps customers understand repairs without feeling overwhelmed: turning technical jargon into relatable stories. I'll cover: Why customers decline work when they don't understand the language How to use simple, everyday analogies (like crayons, sneakers, or coffee filters) The power of humor and storytelling to reduce tension and win trust How to practice analogies as a team for fun, memorable customer experiences A weekly challenge: turn two MPI jobs into analogies and test them with your team When you swap tech talk for real talk, customers nod, laugh, and approve more often. Analogies make the complex simple — and that's where credibility (and sales) live. Dealer Talk with Jen Suzuki Podcast |

As CEO of City West Housing, Leonie King leads a committed team that develops affordable housing and provide housing services to some 1,600 residents in metropolitan Sydney.In this episode, Leonie King will be talking about affordable homes, funding, planning approvals, land costs, how can we get governmental outcomes for housing, private developers, and community housing providers working together to better to solve our housing crisis & much, much more.This podcast is brought to you in association with AWS, proud sponsors of our 2025 Residential series of podcasts.

October always hits different. The pressure to "lock in" for Q4, finish strong, and sprint to December is everywhere. But if you're already working weekends and drowning in Slack pings, that advice just adds weight. In this episode, I'm introducing a new segment: The CEO Briefing - your weekly download on what's happening in the founder space, what patterns I'm seeing on recovery calls, and the signals that should shape how you lead this week. This week's briefing covers: Why Q4 feels heavier than it should (and how to reframe it) The "locking in" trend and why it's broken for most founders The one-day contract that's eating your whole week Where all the energized, well-rested women have gone (and how to become one) Then I break down three filters that will save you 5-10 hours this week: Projects before pings Approvals at intervals Decision filters instead of daily reactions If you're tired of telling yourself "it'll calm down after Q4," this episode is your permission slip to stop waiting and start building the structure that gives you back your evenings, weekends, and energy. Links mentioned: Book a free 30-min Recovery Call: https://docs.google.com/document/d/1YsOE-H1gnkSnDvDTbpUmXLpixgLwDrGq17E2PFTsT6U/edit?usp=sharing  Learn about The CEO Studio (90-day private partnership): https://hollybray.com/studio  If this episode resonated, share it with another founder who needs it, or leave a review to help more people find the show.

October always hits different. The pressure to "lock in" for Q4, finish strong, and sprint to December is everywhere. But if you're already working weekends and drowning in Slack pings, that advice just adds weight. In this episode, I'm introducing a new segment: The CEO Briefing - your weekly download on what's happening in the founder space, what patterns I'm seeing on recovery calls, and the signals that should shape how you lead this week. This week's briefing covers: Why Q4 feels heavier than it should (and how to reframe it) The "locking in" trend and why it's broken for most founders The one-day contract that's eating your whole week Where all the energized, well-rested women have gone (and how to become one) Then I break down three filters that will save you 5-10 hours this week: Projects before pings Approvals at intervals Decision filters instead of daily reactions If you're tired of telling yourself "it'll calm down after Q4," this episode is your permission slip to stop waiting and start building the structure that gives you back your evenings, weekends, and energy. Links mentioned: Book a free 30-min Recovery Call: https://docs.google.com/document/d/1YsOE-H1gnkSnDvDTbpUmXLpixgLwDrGq17E2PFTsT6U/edit?usp=sharing  Learn about The CEO Studio (90-day private partnership): https://hollybray.com/studio  If this episode resonated, share it with another founder who needs it, or leave a review to help more people find the show.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.President Trump has announced a 100% tariff deadline for pharmaceutical companies starting on October 1. However, companies that have already begun construction on manufacturing facilities in the U.S. are exempt from these tariffs. This move is part of the administration's efforts to lower drug prices and improve access to treatments for patients.In other news, Crinetics Pharmaceuticals has received FDA approval for their once-daily treatment for acromegaly, a rare pituitary condition. This approval marks a significant milestone for Crinetics and is expected to have a positive impact on patients' lives.Additionally, Lilly's oral SERD has been approved by the FDA for the treatment of breast cancer. This treatment has shown improved progression-free survival compared to standard therapy, offering new hope for patients battling this disease.The Trump administration is also preparing a proposed rule to further lower drug prices in the U.S., as part of an ongoing effort to align drug prices with other economically similar countries. These developments in the pharmaceutical industry are aimed at improving access to treatments and lowering costs for patients.

Bongani Bingwa speaks to David Fleminger, Chairperson of the Johannesburg Heritage Foundation about the difficulties residents and developers are facing in accessing building plans and allegations that officials have been soliciting bribes of up to R2,000, along with the disruptions caused by the closure of the Metro Centre. 702 Breakfast with Bongani Bingwa is broadcast on 702, a Johannesburg based talk radio station. Bongani makes sense of the news, interviews the key newsmakers of the day, and holds those in power to account on your behalf. The team bring you all you need to know to start your day Thank you for listening to a podcast from 702 Breakfast with Bongani Bingwa Listen live on Primedia+ weekdays from 06:00 and 09:00 (SA Time) to Breakfast with Bongani Bingwa broadcast on 702: https://buff.ly/gk3y0Kj For more from the show go to https://buff.ly/36edSLV or find all the catch-up podcasts here https://buff.ly/zEcM35T Subscribe to the 702 Daily and Weekly Newsletters https://buff.ly/v5mfetc Follow us on social media: 702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/Radio702 702 on YouTube: https://www.youtube.com/@radio702See omnystudio.com/listener for privacy information.

Can an AI‑native general ledger really automate the monthly close without losing control? Blake talks with Digits CEO Jeff Seibert about an “autonomous GL” built on a vector graph model, AI agents that research unknown transactions and auto‑reconcile to pixel‑matched statements, and human‑in‑the‑loop safeguards. Learn where Digits fits best today, how to pilot it with clients, price AI‑powered CAS, and keep trust with audit trails, object‑level permissions, and deterministic reporting.Chapters(01:20) - Understanding Autonomous General Ledgers (02:13) - Technical Architecture of Digits (05:29) - Real-World Application of Digits (10:10) - Advanced Features and Accuracy (16:09) - Automated Reconciliation (19:11) - Innovative Reporting Capabilities (24:19) - AI Agents in Accounting (28:40) - Automating Collections and Approvals (29:59) - Customizing Agent Instructions (30:46) - Balancing Simplicity and Complexity in Product Design (46:42) - Impact of AI on Accounting Roles (48:26) - Learning and Adapting to AI in Accounting (52:45) - Conclusion and Next Steps Sign up to get free CPE for listening to this podcasthttps://earmarkcpe.comhttps://earmark.app/Download the Earmark CPE App Apple: https://apps.apple.com/us/app/earmark-cpe/id1562599728Android: https://play.google.com/store/apps/details?id=com.earmarkcpe.appConnect with Our Guest, Jeff SeibertWebsite: https://jeffseibert.com/LinkedIn: https://www.linkedin.com/in/jseibert/Learn more about DigitsWebsite: https://digits.com/Connect with Blake Oliver, CPALinkedIn: https://www.linkedin.com/in/blaketoliverTwitter: https://twitter.com/blaketoliver/

Thank you so much for listening to the Bob Harden Show, celebrating over 14 years broadcasting on the internet. On Tuesday's show, we visit with Florida State Senator Kathleen Passidomo about the assassination of Charlie Kirk and his celebration of life. We visit with Energy Policy Expert for Americans for Prosperity Faith Burns about the vulnerability of our energy grid and the need to speed up regulatory approvals. Boo Mortenson and I discuss some of the benefits but also the threats of Artificial Intelligence to human intelligence and development. We also visit Linda Harden about President Trump's announcement yesterday about developing science on autism and vaccine schedules. Please join us tomorrow when we visit with Cato Institute Chairman Emeritus Bob Levy and Professor Andrew Joppa. Access this or past shows at your convenience on my web site, social media platforms or podcast platforms.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Pfizer has made a comeback in the obesity market with the acquisition of Metsera for $4.9 billion, rejuvenating its portfolio after facing challenges with three discontinued assets. Meanwhile, Stealth BioTherapeutics has received expedited FDA approval for the first-ever treatment for Barth syndrome, and Sanofi's decision on their oral multiple sclerosis drug has been postponed to December. The ACIP committee has expressed concerns about a lack of knowledge and experience within the reconstituted committee. Biotility offers industry-recognized credentials to advance bioscience careers, Novartis is exploring ways to reduce drug costs in the US, and Merck has received approval for a subcutaneous formulation of Keytruda. Stay tuned for more updates on the psychedelics space, rare disease treatments, and other developments in the biopharmaceutical industry.

Thank you so much for listening to the Bob Harden Show, celebrating over 14 years broadcasting on the internet. On Tuesday's show, we visit with Florida State Senator Kathleen Passidomo about the assassination of Charlie Kirk and his celebration of life. We visit with Energy Policy Expert for Americans for Prosperity Faith Burns about the … The post The Vulnerability of Our Energy Grid and the Need to Speed Up Regulatory Approvals appeared first on Bob Harden Show.

Joyce discusses the approval of 48 of President Trump's picks in a single vote following rule changes. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Today is Friday, Sept. 19, 2025. The Brainerd Dispatch Minute is a product of Forum Communications Co. and is brought to you by reporters at the Brainerd Dispatch. Find more news throughout the day at BrainerdDispatch.com.

We are talking Ghostbusters on the April 2024 Party in the Back Podcast. President of Business Operations from the Fort Wayne Komets Scott Sproat and Jon Long Manager the Event Presentation & Creative Content for the Edmonton Oil Kings join the podcast to talk about their success with this Movie theme night.Scott and Jon drop insights on all aspects of their promotion, including:Approvals and support from movie studio and rights holdersLeading their team's creative effortPopular fan elements for their Ghostbusters NightSocial Media elementsScoreboard additionsJersey Auctions, like the Komets $13,000 charity jersey auctionMusic and bumpers, including a one night change in the Oil Kings Goal songSponsor integrations and more...

First impressions are money in the service drive. In this episode of Dealer Talk with Jen Suzuki, we dig into the relational greeting — the difference between being just another transactional advisor and being the trusted pro customers return to again and again. I'll walk you through how to: Show up with the right energy (because customers feel it before you speak) Use names, humor, and personal touches to build instant trust Transition naturally from small talk to business without feeling “robo” Make customers feel like people, not VIN numbers Turn a check-in into the start of a relationship that drives approvals and loyalty This isn't theory — it's what I see working every week in dealerships. If your service team can nail this, the rest of the process gets easier, approvals go up, and income potential climbs. Dealer Talk with Jen Suzuki Podcast |

How do you get your executive pastor to give a "yes" to all your requests?We're joined by our Southeast Church friends today to continue our Executive Pastor and Tech podcast series. In this episode you'll hear: 1:00 Blake's hilarious church tech mic moment4:55 Southeast Christian Church team joins the podcast6:50 Five Truths and a Lie: church production edition16:00 What an executive pastor really does in church leadership18:30 How church techs can build trust with their executive pastor23:15 How to get a “yes” from your executive pastor as a church tech33:15 The right way to ask your executive pastor for resources or budget41:30 When church gear fails (and you warned it would)45:45 System failure stories in church production52:00 Why the church tech–integrator relationship matters1:01:00 Handling tension with your executive pastor as a church production leader1:07:10 Why church techs should talk about non-work things with pastorsCheckout HouseRight's solutions for your church and open jobs here. Resources for your Church Tech Ministry Sell Us Gear: Does your church have used gear that you need to convert into new ministry dollars? We can make you an offer here. Buy Our Gear: Do you need some production gear but lack the budget to buy new gear? You can shop our gear store here. Connect with us: Sales Bulletin: Get better deals than the public and get them earlier too here! Early Service: Get our best gear before it goes live on our site here. Instagram: Hangout with us on the gram here! Reviews: Leaving us a review on the podcast player you're listening to us on really helps the show. If you enjoyed this episode, you can say thank you with a review!

This one's for the service team (but sales, you should listen too—because everybody's in sales). In this kickoff to my new Service Team Series on Dealer Talk with Jen Suzuki, I break down the Service Cheat Code: how preparation before the customer even shows up changes everything. From reviewing history and declined work to checking recalls, parts, and notes, I share the exact steps that turn rushed, transactional check-ins into confident, relational experiences that win trust and drive approvals. These are the same hacks I train advisors on in dealerships every single week—practical, now, and proven to increase income potential. This episode is your game plan for better connections, smoother days, and higher CSI scores. Dealer Talk with Jen Suzuki Podcast |

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago. In this episode, OncLive On Air® partnered with Two Onc Docs to feature a conversation about soft tissue sarcoma management. Drs Armstrong and Tawagi discussed that soft tissue sarcomas represent a rare and heterogeneous group of malignancies that arise from mesenchymal cells rather than epithelial cells and encompass several distinct histologic subtypes. They explained that although uncommon, these sarcomas are frequently emphasized in board examinations, partly because their management has historically been stable, though recent FDA approvals and ongoing research have expanded therapeutic options. They noted that risk factors may include prior radiation exposure, environmental agents, and viral infections. Additionally, they shared that chronic lymphedema is associated with angiosarcoma, whereas rare hereditary syndromes may predispose individuals to specific sarcoma subtypes.  Clinically, they explained that sarcomas may arise anywhere in the body, though many occur in the thigh, buttocks, or groin, typically presenting as painless, enlarging masses often mistaken for benign lesions. They emphasized that diagnosis requires core needle biopsy to preserve tissue architecture and that staging relies on MRI of the primary site and CT of the chest, given the strong predilection for pulmonary metastases. They also summarized the five subtypes of soft tissue sarcoma—synovial, clear cell, angiosarcoma, rhabdomyosarcoma, and epithelioid. They reported that the cornerstone of localized disease management is surgical resection, preferably limb-sparing when feasible, combined with radiation for larger or high-risk tumors. They also highlighted novel strategies like immunotherapy. For metastatic disease, they stated that surgical resection of pulmonary metastases can achieve durable remissions in select patients. 

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Robert F. Kennedy Jr. faced the Senate Finance Committee in a tense hearing amidst calls for the removal of the health secretary. The committee questioned Kennedy on his recent actions, including the firing of CDC director Susan Monarez. Meanwhile, the FDA's new rare disease pathway received mixed reactions, with some questioning its tangible impacts. AC Immune downsized and refocused its pipeline, while Kennedy proposed adding seven new vaccine advisors to the ACIP. Other news included successful RNA editing in an AATD study, demands for YouTube to remove anti-vaccine videos, and a new framework for rare disease approvals by the FDA. Thank you for tuning in to today's episode of Pharma and Biotech daily.

Following its 2024 overhaul, MM2H posted an 84% boost in inflows, including RM237 million in property and RM597 million in deposits.View the full article here.Subscribe to the IMI Daily newsletter here. 

US President Donald Trump signed the “Enabling Competition In The Commercial Space Industry” Executive Order (EO). Gilat Satellite Networks has been awarded a multimillion dollar contract by Israel's Ministry of Defense for the delivery and integration of satellite communication systems (SATCOM) and services. The Italian Space Agency (ASI) has signed an agreement with SpaceX for an uncrewed mission to Mars aboard a future Starship mission, and more. Remember to leave us a 5-star rating and review in your favorite podcast app. Be sure to follow T-Minus on LinkedIn and Instagram. T-Minus Guest Our guest today is Luis Torres, founder of Torres Orbital Mining (TOM).  You can connect with Luis on LinkedIn, and find out more about TOM on their website. Selected Reading Enabling Competition in the Commercial Space Industry – The White House Gilat receives a multimillion contract from Israel's Ministry of Defense for advanced strategic defense SATCOM project Agenzia Spaziale ITA (@ASI_spazio) / X Spire Global Announces Preliminary Second Quarter 2025 Revenue and Provides Business Update KBR and Axiom Space Successfully Complete Initial Crewed Spacesuit Tests in NASA's Neutral Buoyancy Lab Space Kinetic Corp. LinkedIn This real 'Eye of Sauron' spits out ghost particles in space. Here's what it looks like T-Minus Crew Survey Complete our annual audience survey before August 31. Want to hear your company in the show? You too can reach the most influential leaders and operators in the industry. Here's our media kit. Contact us at space@n2k.com to request more info. Want to join us for an interview? Please send your pitch to space-editor@n2k.com and include your name, affiliation, and topic proposal. T-Minus is a production of N2K Networks, your source for strategic workforce intelligence. © N2K Networks, Inc. Learn more about your ad choices. Visit megaphone.fm/adchoices

Shoot us a Text.Episode #1118: Auto loan approvals are climbing as vehicle demand heats up, Jaguar doubles down on its high-dollar EV future, and a new survey shows U.S. shoppers are still splurging on impulse buys.Show Notes with links:New data shows consumers may finally be catching a break in the auto loan market. Approvals are up, interest in buying is growing, and middle-income shoppers are more willing to make sacrifices to keep their vehicles.The New York Fed says auto loan rejection rates dropped sharply in Q2 2025 to 6.7%, down from a painful 19% last year.14% sought a loan in the past year, and more expect to apply in the coming months.Santander's latest survey shows 55% of middle-income consumers plan to buy a vehicle in the next 12 months, the highest reading in two years.Tariff fears are real: 18% of respondents sped up a big purchase in Q2 because of price uncertainty, with 41% of those buying a vehicle.Santander says this is the first time in eight quarters that buyers outnumber those delaying a purchase — a sign pent-up demand could finally be turning into sales.Jaguar is set on an electric, ultra-luxury future. Despite some loud critics, the brand is preparing a bespoke EV platform and three six-figure models designed to take on the industry's elite.Incoming JLR CEO PB Balaji says the brand's EV strategy is locked in, with positive early feedback from customers.Production of all current Jaguars except the F-Pace ended last year as the company stockpiled inventory.First new model — the GT — is a sleek, 600-hp electric sedan with about 425 miles of range and a $150K price tag, expected late next year as a 2027 model.A large, three-row electric crossover will follow in late 2027 or early 2028.The third entry is rumored to be a large, ultra-luxury electric sedan aimed at Rolls-Royce and Bentley buyers, due around 2030.While many Americans say they're trying to rein in discretionary spending, a new survey shows the vast majority still made at least one unplanned purchase last month.Optimum Retailing survey finds 72% of Americans made an unplanned in-store discretionary purchase in the past month.While 34% plan to cut back in the next six months, sales events (55%), eye-catching displays (45%), and immediate availability (26%) make spending hard to resist.Only 5% said in-store shopping no longer feels “worth it.”Many shoppers are sticking to a budget by cutting dining/takeout (48%), clothing/accessories (44%), and electronics/gadgets (37%).“Consumers today are cautious, but not unengaged… The moment and experience must both feel correct,” said Sam Vise, CEO of Optimum Retailing.Join Paul J Daly and Kyle Mountsier every morning for the Automotive State of the Union podcast as they connect the dots across car dealerships, retail trends, emerging tech like AI, and cultural shifts—bringing clarity, speed, and people-first insight to automotive leaders navigating a rapidly changing industry.Get the Daily Push Back email at https://www.asotu.com/ JOIN the conversation on LinkedIn at: https://www.linkedin.com/company/asotu/

Anton from Drop Ship Lifestyle addresses a common question regarding the difficulty of obtaining brand authorization using his dropshipping techniques. He details the process and shares tips for securing brand approval, highlighting the importance of building a strong brand presence for business growth. Learn about brand approval and how to make money online!